The introduction of endothelin 1 receptor antagonists and phosphodiesterase type 5 inhibitor for PAH at the beginning of the twenty-first century has significantly improved pulmonary hemodynamics and clinical outcomes [16,17]. The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.